Xenon Pharmaceuticals Q3 2026 net loss widens 21% to $110.4 million

• Xenon Pharmaceuticals’ third-quarter 2026 net loss widened 21% year over year to $110.4 million.
• Research and development expenses rose 24% year over year to $95.6 million.
• Cash, cash equivalents and marketable securities totaled $1.15 billion at September 30, 2026, with funding expected to support operations into 2029.
• The azetukalner application for focal seizures was submitted to the FDA in September 2026.
• Enrollment in the Phase 3 X-NOVA2 depression study finished, with topline results now expected in December 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-453521), on November 09, 2026, and is solely responsible for the information contained therein.